Pharma major Lupin Limited
(Lupin) announced the launch of Levothyroxine Sodium Tablets USP, having received approval from the USFDA earlier.
Lupin’s Levothyroxine Sodium Tablets USP, is the generic equivalent of AbbVie, Inc’s Synthroid Tablets, as per BSE filing. It is indicated for:
Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism
Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer
Levothyroxine Sodium Tablets, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg had an annual sale of approximately $2.5bn in the U.S (IQVIA MAT January 2019), the company added.
Lupin Ltd is currently trading at Rs748.15 down by Rs4.4 or 0.58% from its previous closing of Rs752.55 on the BSE.
The scrip opened at Rs756 and has touched a high and low of Rs757.15 and Rs746.50 respectively. So far 7,87,308 (NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs34,051.62cr.